Method for treating established spontaneous auto-immune diseases in mammals

Abstract

A method of treating spontaneous and ongoing auto-immune diseases in mammals, comprising administering to a mammal, in need of such a treatment, a therapeutically effective amount of one or more non mitogenic anti-CD3 active principles to achieve permanent disease remission through the induction of antigen-specific unresponsiveness, i.e. immune tolerance.

1 - 15 . (canceled)  
     
     
         16 . A method of treating an ongoing autoimmune disease in a human having said disease, wherein said disease is psoriasis, comprising: 
 treating said human by administering one or more non-mitogenic anti-CD3 active compounds selected from the group consisting of CD3 antibodies and fragments of CD3 antibodies in an amount effective to treat said psoriasis.    
     
     
         17 . The method of  claim 16  wherein said treatment results in a durable remission of said psoriasis.  
     
     
         18 . The method of  claim 16  wherein said administration of said one or more non-mitogenic anti-CD3 active compounds is a non-chronic administration.  
     
     
         19 . The method of  claim 16  wherein said non-mitogenic anti-CD3 active compound is a non-mitogenic anti-CD3 monoclonal antibody (Fab′) 2  fragment.  
     
     
         20 . The method of  claim 16  wherein said non-mitogenic anti-CD3 active compound is a non-mitogenic anti-CD3 antibody.  
     
     
         21 . The method of  claim 20  wherein said non-mitogenic anti-CD3 active compound is a non-mitogenic anti-CD3 monoclonal antibody.  
     
     
         22 . The method of  claim 21  wherein said monoclonal antibody is selected from the group consisting of murine or humanized antibody.  
     
     
         23 . The method of  claim 16  wherein said compound is highly purified and endotoxin-free.  
     
     
         24 . The method of  claim 16  wherein said active compound is administered by injection.  
     
     
         25 . The method of  claim 16  wherein said non-mitogenic anti-CD3 active compound is administered in an injectable form that contains from 5 to 20 mg of the non-mitogenic anti-CD3 active compound.